The vision of Life Science Leader is to be an essential business tool for life science executives. Our content is designed to not only inform readers of best practices, but motivate them to implement those best practices in their own businesses.
Issue link: https://lifescienceleadermag.epubxp.com/i/183291
BIO INNOVATION NOTES Innovation In Alternative Chromatography By Eric Langer, president and managing partner, BioPlan Associates, Inc. F or years, many biopharma industry manufacturers have said the use of Protein A chromatography for purifying biologics (a mainstay process) isn't broken, so why fix it? However, Protein A media remains a major thorn in the side of operators due to its high cost, as well as the cost of recycling and cleaning/ validation. Alternative technologies for purification of antibodies have been and are being developed with longer lifetimes and therefore, lower cost-per-unit of protein produced. The industry continues to show significant interest in alternatives to Protein A this year, although that interest appears to have waned somewhat from prior years. Results from our 10th Annual Report and Survey of Biopharmaceutical Manufacturers (see www. bioplanassociates.com/10th) indicate that 33 percent of the industry is considering alternatives to Protein A for new production units. That's a significant step back from a range of 51 percent to 61 percent expressing such an interest in the four previous years. Furthermore, this year 1 in 10 respondents "agreed" or "strongly agreed" that they are considering alternatives to Protein A for existing production units. Consideration of alternatives for existing production has been on a decline for four consecutive years, down from 27.1 percent expressing interest in 2009. While fewer respondents this year claimed active consideration of alternatives, the proportion planning to move away from Protein A for existing scale-up or commercial production units over the next 12 months has remained steady. This year, 14 percent of respondents indicated that to be the case, double last year's percentage, but more in line with results from 2011 (15 percent) and 2009 (12 percent). It should be noted that, this year, very few noted that they "strongly agree" with the statements. So, respondents don't appear to have very committed views in this area. As downstream operations improve, the industry is recognizing that, while it is open to considering Protein A alternatives, this isn't a burning topic. In addition, few viable alternatives are currently available or at least proven and documented to be cost-effective at large scale. Thus, most of the industry has not yet formed strong opinions and are sticking with Protein A products for lack of better, cheaper 20 LifeScienceLeader.com October 2013 alternatives. The prevailing opinion, then, seems to be that Protein A works well enough. MANY HAVE INTEREST; FEW MAKE THE SWITCH The gap between interest and behavior when it comes to Protein A alternatives is evident in other results from this year's study. In our in-depth exploration of downstream operations, we asked respondents to indicate the various activities their organizations have engaged in to improve downstream purification operations. Tellingly, while about one-quarter (23.8 percent) of the respondents claimed to have investigated alternatives to Protein A, just 4.8 percent said they had actually switched to alternatives. That follows a pattern seen in past years: in 2012, 21 percent indicated they had investigated alternatives, while 10 percent had made the switch; in 2011, the figures were 31 percent and 11 percent, respectively. Aside from demonstrating that far fewer respondents switch to Protein A alternatives than investigate them, the results also show that the percentage who have switched to alternatives is in the midst of a multiyear decline. That may not change soon. That's because CMOs appear to have less interest in switching to Protein A alternatives than innovators. This year, while a relatively equal percentage explored alternatives (23 percent for biomanufacturers, 25 percent for CMOs), no CMOs reported switching, compared to 5 percent of biomanufacturers who did so. Given that other results from our study suggest that CMOs tend to be leading indicators of future innovator trends, there's reason to believe that developers won't be flocking to alternatives anytime soon. There are also some fascinating differences when sorting the responses into three geographic regions: the United States, Western Europe, and the rest of the world (ROW). Among U.S. respondents, one-quarter claimed to have investigated alternatives to Protein A in order to improve downstream operations, although none switched to alternatives. By contrast, while fewer European respondents explored alternatives (14 percent), a significant 7 percent switched. And finally, respondents from the rest of the world were both most likely to have investigated alternatives to Protein A (30